These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 21124075)

  • 41. A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer: ParvOryx02 protocol.
    Hajda J; Lehmann M; Krebs O; Kieser M; Geletneky K; Jäger D; Dahm M; Huber B; Schöning T; Sedlaczek O; Stenzinger A; Halama N; Daniel V; Leuchs B; Angelova A; Rommelaere J; Engeland CE; Springfeld C; Ungerechts G
    BMC Cancer; 2017 Aug; 17(1):576. PubMed ID: 28851316
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Stability and safety key factors of the oncolytic protoparvovirus H-1 from manufacturing to human application.
    Frehtman V; Wohlfarth D; Müller M; Krebs O; Leuchs B
    Appl Microbiol Biotechnol; 2023 Aug; 107(15):4777-4787. PubMed ID: 37209160
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol.
    Geletneky K; Huesing J; Rommelaere J; Schlehofer JR; Leuchs B; Dahm M; Krebs O; von Knebel Doeberitz M; Huber B; Hajda J
    BMC Cancer; 2012 Mar; 12():99. PubMed ID: 22436661
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Oncolytic rat parvovirus H-1PV, a candidate for the treatment of human lymphoma: In vitro and in vivo studies.
    Angelova AL; Aprahamian M; Balboni G; Delecluse HJ; Feederle R; Kiprianova I; Grekova SP; Galabov AS; Witzens-Harig M; Ho AD; Rommelaere J; Raykov Z
    Mol Ther; 2009 Jul; 17(7):1164-72. PubMed ID: 19367260
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Synergistic combination of valproic acid and oncolytic parvovirus H-1PV as a potential therapy against cervical and pancreatic carcinomas.
    Li J; Bonifati S; Hristov G; Marttila T; Valmary-Degano S; Stanzel S; Schnölzer M; Mougin C; Aprahamian M; Grekova SP; Raykov Z; Rommelaere J; Marchini A
    EMBO Mol Med; 2013 Oct; 5(10):1537-55. PubMed ID: 24092664
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.
    Hajda J; Leuchs B; Angelova AL; Frehtman V; Rommelaere J; Mertens M; Pilz M; Kieser M; Krebs O; Dahm M; Huber B; Engeland CE; Mavratzas A; Hohmann N; Schreiber J; Jäger D; Halama N; Sedlaczek O; Gaida MM; Daniel V; Springfeld C; Ungerechts G
    Clin Cancer Res; 2021 Oct; 27(20):5546-5556. PubMed ID: 34426438
    [TBL] [Abstract][Full Text] [Related]  

  • 47. H-1 Parvovirus-Induced Oncolysis and Tumor Microenvironment Immune Modulation in a Novel Heterotypic Spheroid Model of Cutaneous T-Cell Lymphoma.
    Angelova A; Barf M; Just A; Leuchs B; Rommelaere J; Ungerechts G
    Cancers (Basel); 2024 Jul; 16(15):. PubMed ID: 39123440
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anticancer effects of an oncolytic parvovirus combined with non-conventional therapeutics on pancreatic carcinoma cell lines.
    Raykov Z; Georgieva PB; Angelova A; Galabov AS; Rommelaere J
    Acta Virol; 2009; 53(1):57-60. PubMed ID: 19301953
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Oncolytic poliovirus therapy and immunization with poliovirus-infected cell lysate induces potent antitumor immunity against neuroblastoma in vivo.
    Toyoda H; Wimmer E; Cello J
    Int J Oncol; 2011 Jan; 38(1):81-7. PubMed ID: 21109928
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity.
    Giezeman-Smits KM; Okada H; Brissette-Storkus CS; Villa LA; Attanucci J; Lotze MT; Pollack IF; Bozik ME; Chambers WH
    Cancer Res; 2000 May; 60(9):2449-57. PubMed ID: 10811123
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oncolytic parvoviruses: from basic virology to clinical applications.
    Marchini A; Bonifati S; Scott EM; Angelova AL; Rommelaere J
    Virol J; 2015 Jan; 12():6. PubMed ID: 25630937
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Oncolytic Virotherapy Era in Cancer Management: Prospects of Applying H-1 Parvovirus to Treat Blood and Solid Cancers.
    Angelova AL; Witzens-Harig M; Galabov AS; Rommelaere J
    Front Oncol; 2017; 7():93. PubMed ID: 28553616
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Viro-immune therapy: A new strategy for treatment of pancreatic cancer.
    Ibrahim AM; Wang YH
    World J Gastroenterol; 2016 Jan; 22(2):748-63. PubMed ID: 26811622
    [TBL] [Abstract][Full Text] [Related]  

  • 54. "Infectious tolerance" develops after the spontaneous acceptance of Lewis-to-Dark Agouti rat liver transplants.
    Kataoka M; Margenthaler JA; Ku G; Eilers M; Flye MW
    Surgery; 2003 Aug; 134(2):227-34. PubMed ID: 12947322
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Analysis of Th1 and Th2 cytokines expressing CD4+ and CD8+ T cells in rheumatoid arthritis by flow cytometry.
    Berner B; Akça D; Jung T; Muller GA; Reuss-Borst MA
    J Rheumatol; 2000 May; 27(5):1128-35. PubMed ID: 10813277
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Activation of a glioma-specific immune response by oncolytic parvovirus Minute Virus of Mice infection.
    Grekova SP; Raykov Z; Zawatzky R; Rommelaere J; Koch U
    Cancer Gene Ther; 2012 Jul; 19(7):468-75. PubMed ID: 22539062
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immune System Stimulation by Oncolytic Rodent Protoparvoviruses.
    Angelova A; Rommelaere J
    Viruses; 2019 May; 11(5):. PubMed ID: 31060205
    [TBL] [Abstract][Full Text] [Related]  

  • 58. PKCη/Rdx-driven phosphorylation of PDK1: a novel mechanism promoting cancer cell survival and permissiveness for parvovirus-induced lysis.
    Bär S; Rommelaere J; Nüesch JP
    PLoS Pathog; 2015 Mar; 11(3):e1004703. PubMed ID: 25742010
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Molecular pathways: rodent parvoviruses--mechanisms of oncolysis and prospects for clinical cancer treatment.
    Nüesch JP; Lacroix J; Marchini A; Rommelaere J
    Clin Cancer Res; 2012 Jul; 18(13):3516-23. PubMed ID: 22566376
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Induction of strong antitumor immunity by an HSV-2-based oncolytic virus in a murine mammary tumor model.
    Li H; Dutuor A; Fu X; Zhang X
    J Gene Med; 2007 Mar; 9(3):161-9. PubMed ID: 17266169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.